Windtree Therapeutics (NASDAQ:WINT) Shares Scheduled to Reverse Split on Monday, April 22nd

Windtree Therapeutics, Inc. (NASDAQ:WINT) shares are going to reverse split before the market opens on Monday, April 22nd. The 1-18 reverse split was announced on Monday, April 22nd. The number of shares owned by shareholders will be adjusted after the market closes on Monday, April 22nd.

Windtree Therapeutics Price Performance

Shares of NASDAQ:WINT traded down $0.06 during midday trading on Thursday, hitting $0.34. The company had a trading volume of 1,789,008 shares, compared to its average volume of 280,849. Windtree Therapeutics has a twelve month low of $0.27 and a twelve month high of $7.79. The company has a debt-to-equity ratio of 2.00, a current ratio of 2.40 and a quick ratio of 2.40. The stock has a market cap of $1.75 million, a price-to-earnings ratio of -0.04 and a beta of 0.61. The business’s 50-day simple moving average is $0.37 and its 200-day simple moving average is $0.67.

Analyst Upgrades and Downgrades

Separately, HC Wainwright reissued a “neutral” rating on shares of Windtree Therapeutics in a research note on Wednesday, January 3rd.

Institutional Investors Weigh In On Windtree Therapeutics

Hedge funds and other institutional investors have recently added to or reduced their stakes in the business. Citadel Advisors LLC acquired a new stake in Windtree Therapeutics during the second quarter worth $27,000. Virtu Financial LLC acquired a new stake in Windtree Therapeutics during the fourth quarter worth $28,000. Vanguard Group Inc. acquired a new stake in Windtree Therapeutics during the third quarter worth $40,000. Millennium Management LLC increased its stake in Windtree Therapeutics by 411.1% during the second quarter. Millennium Management LLC now owns 79,858 shares of the company’s stock worth $33,000 after acquiring an additional 64,232 shares during the last quarter. Finally, Envestnet Asset Management Inc. increased its stake in Windtree Therapeutics by 894.7% during the third quarter. Envestnet Asset Management Inc. now owns 107,302 shares of the company’s stock worth $32,000 after acquiring an additional 96,515 shares during the last quarter. Institutional investors and hedge funds own 29.33% of the company’s stock.

About Windtree Therapeutics

Windtree Therapeutics, Inc, a clinical-stage biopharmaceutical company, focuses on the development of therapeutics for the treatment of acute cardiovascular diseases. The company's lead development programs include istaroxime, which is in Phase 2b clinical trial for the treatment of acute decompensated heart failure, as well as in Phase 2a clinical trial for the treatment of early cardiogenic shock; AEROSURF, an aerosolized KL4 surfactant, which is in Phase 2b clinical trial to treat respiratory distress syndrome in premature infants; Surfaxin, a lyophilized KL4 surfactant, which is in Phase 2a clinical trial for the treatment of lung injury resulting from COVID-19; Rostafuroxin that is in Phase 2b clinical trial for the treatment of genetically associated hypertension; and oral and intravenous SERCA2a activator, which is in preclinical trial for the treatment of chronic and acute heart failure.